Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
177Lu-DTPA-SC16.56 in High-grade Neuroendocrine Carcinomas of the Lung and Prostate
NCT06941480Phase 1Not yet recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Dec 2026
- Primary completion
- May 2030
- Modality
- Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 1, open-label trial of 177Lu-DTPA-SC16.56 in neuroendocrine carcinoma of the lung and neuroendocrine prostate cancer (NEPC) (2 arms), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Maximum Tolerated Dose at 36 months. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
177Lu-DTPA-SC16.56
03
Conditions
neuroendocrine carcinoma of the lungneuroendocrine prostate cancer (NEPC)
Beyond the preview
Go deeper on NCT06941480.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06941480.